1875 Stock Overview
An investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in China.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 1875 from our risk checks.
TOT BIOPHARM International Company Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$2.58 |
52 Week High | HK$3.40 |
52 Week Low | HK$0.80 |
Beta | 0.22 |
11 Month Change | 27.72% |
3 Month Change | 63.29% |
1 Year Change | 14.16% |
33 Year Change | -43.17% |
5 Year Change | n/a |
Change since IPO | -58.79% |
Recent News & Updates
We Think Some Shareholders May Hesitate To Increase TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation
Jun 07The Market Lifts TOT BIOPHARM International Company Limited (HKG:1875) Shares 29% But It Can Do More
May 21Is TOT BIOPHARM International (HKG:1875) Using Debt In A Risky Way?
Mar 18Recent updates
We Think Some Shareholders May Hesitate To Increase TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation
Jun 07The Market Lifts TOT BIOPHARM International Company Limited (HKG:1875) Shares 29% But It Can Do More
May 21Is TOT BIOPHARM International (HKG:1875) Using Debt In A Risky Way?
Mar 18There's No Escaping TOT BIOPHARM International Company Limited's (HKG:1875) Muted Revenues
Dec 28Does TOT BIOPHARM International (HKG:1875) Have A Healthy Balance Sheet?
Nov 23We Think TOT BIOPHARM International (HKG:1875) Has A Fair Chunk Of Debt
May 18Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation
Jul 27An Intrinsic Calculation For TOT BIOPHARM International Company Limited (HKG:1875) Suggests It's 41% Undervalued
Mar 26Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation
Feb 03Shareholder Returns
1875 | HK Biotechs | HK Market | |
---|---|---|---|
7D | 10.7% | 1.8% | 2.7% |
1Y | 14.2% | -34.3% | 2.1% |
Return vs Industry: 1875 exceeded the Hong Kong Biotechs industry which returned -34.3% over the past year.
Return vs Market: 1875 exceeded the Hong Kong Market which returned 2.1% over the past year.
Price Volatility
1875 volatility | |
---|---|
1875 Average Weekly Movement | 9.2% |
Biotechs Industry Average Movement | 8.8% |
Market Average Movement | 7.2% |
10% most volatile stocks in HK Market | 15.3% |
10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 1875's share price has been volatile over the past 3 months.
Volatility Over Time: 1875's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 552 | Jun Liu | www.totbiopharm.com |
TOT BIOPHARM International Company Limited, an investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in China. The company develops and markets Pusintin, a bevacizumab injection for the treatment of non-squamous non-small cell lung cancer; metastatic colorectal cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; cervical cancer; and hepatocellular carcinoma. It also offers Tazian, a temozolomide capsule for the treatment of glioblastoma multiforme or anaplastic astrocytoma; and Megaxia, a megestrol acetate oral suspension for the treatment of anorexia associated with acquired immunode¬ciency syndrome, as well as signi¬cant weight loss of AIDS and cancer patients caused by cachexia.
TOT BIOPHARM International Company Limited Fundamentals Summary
1875 fundamental statistics | |
---|---|
Market cap | HK$1.99b |
Earnings (TTM) | -HK$40.59m |
Revenue (TTM) | HK$839.26m |
2.4x
P/S Ratio-49.1x
P/E RatioIs 1875 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1875 income statement (TTM) | |
---|---|
Revenue | CN¥780.63m |
Cost of Revenue | CN¥206.64m |
Gross Profit | CN¥573.99m |
Other Expenses | CN¥611.74m |
Earnings | -CN¥37.76m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.049 |
Gross Margin | 73.53% |
Net Profit Margin | -4.84% |
Debt/Equity Ratio | 50.1% |
How did 1875 perform over the long term?
See historical performance and comparison